BioCentury | Jun 28, 2018
Distillery Techniques

Biomarkers

...myopia and SNPs on 161 loci, 124 of which were previously unreported, including cytochrome P450 26A1 (CYP26A1; CP26...
...2018 doi:10.1038/s41588-018-0127-7 Contact: Caroline Klaver, Erasmus University Rotterdam, Rotterdam, the Netherlands email: c.c.w.klaver@erasmusmc.nl Mark Zipkin Erasmus University Rotterdam Cytochrome P450 26A1 (CYP26A1) (CP26) Potassium...
BioCentury | Apr 11, 2017
Distillery Techniques

Drug properties; other

...ATRA in mice, metabolic clearance of ATRA, and ATRA-induced expression of cytochrome P450 26A1 ( CYP26A1 ; CP26...
...doi:10.1124/jpet.117.240523 CONTACT: Nina Isoherranen, University of Washington, Seattle, Wash. email: ni2@u.washington.edu Hongjiang Li University of Washington 14 alpha-sterol demethylase Cytochrome P450 26A1 (CYP26A1) (CP26) Retinoic...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1); cytochrome P450 26A1 (CYP26A1; CP26)

...ALDH1A1 - which participates in the biosynthesis of ATRA - were lower, and levels of CYP26A1...
...CYP26A1 expression and tumor growth compared with vehicle. Also in the model, ATRA or a pan-CYP26A1...
...testing to treat acne. TARGET/MARKER/PATHWAY: Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) ; cytochrome P450 26A1 (CYP26A1; CP26...
BioCentury | Mar 27, 2014
Targets & Mechanisms

Insights into ependymoma

Two independent studies have illuminated the fine molecular details of ependymoma tumors and identified targets for a previously intractable disease. A St. Jude Children's Research Hospital team focused on forebrain ependymomas and identified a fusion...
BioCentury | Dec 5, 2005
Clinical News

VTP-201227: Phase II started

Vitae began a double-blind, placebo-controlled, U.S. Phase II trial in 128 patients. Vitae Pharmaceuticals Inc. , Fort Washington, Penn. Product: VTP-201227 Business: Autoimmune Molecular target: NA Description: Topical inhibitor of the enzymes CYP26A and CYP26B Indication:...
BioCentury | Aug 25, 2003
Company News

Cytochroma other research news

Cytochroma said it discovered CYP26C, a member of the cytochrome P450 family. The company said that due to the tissue distribution of CYP26C, inhibitors of the enzyme could be useful in treating CNS disorders. Cytochroma...
Items per page:
1 - 6 of 6